BBL/ SECT/21/2026-27

Date: 13 August 2026

To,
The Listing Department
National Stock Exchange of India Limited,
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai - 400 051

NSE Symbol: BANKA

Dear Sir/Madam,

Sub: Outcome of Board Meeting dated 13 August 2026 and Integrated Filings (Financial)

Ref: Regulation 30 & 33 read with sub-para 4 of Para "A" of Part "A" of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").

This is to inform you that the Board of Directors at its Meeting held today, i.e., 13 August 2026, considered and approved the following:

1) Unaudited standalone and consolidated financial results of the Company for the quarter and three months ended 30 June 2026, based on recommendation of Audit Committee.

2) Limited Review Reports (standalone and consolidated) thereon, for the quarter and three months ended 30 June 2026, based on recommendation of Audit Committee.

   A copy of the aforementioned Financial Results along with the Auditors' Reports thereon pursuant to Regulation 33 of SEBI Listing Regulations are enclosed herewith.

   We are also arranging to upload the aforesaid Financial Results on the Company's website at https://www.bankabio.com/investors and shall publish the Financial Results in the newspapers, in the format prescribed under Regulation 47 of the SEBI Listing Regulations.

3) Based on recommendation of Nomination and Remuneration Committee and subject to approval of members of the Company, in the ensuing Annual General Meeting, re-appointment of Mrs. Namita Sanjay Banka (DIN: 05017358) as Managing Director of the Company, who retires by rotation, and being eligible offers herself for re-appointment. *(Details provided in Annexure I)*

4) Approved the Board Report, along with its annexures, for the year ended 31 March 2026 along with Management Discussion and Analysis Report, Corporate Governance Report and Secretarial Audit Report.

5) Approved and adopted following amended policies:

- Policy on related party transactions
- Policy on material subsidiary of the Company

These are being uploaded at website of the Company at https://www.bankabio.com/investors.

6) Approved holding of 14th Annual General Meeting of the Company on Thursday, 17 September 2026, through video conferencing/other audio video visual means (VC/OAVM) at along with approving the notice of said Annual General Meeting.

7) Appointment of Mr. M Ramana Reddy, (C P No. 18415), Practicing Company Secretary, as Scrutinizer for the purpose of 14th Annual General Meeting of the Company.

8) Based on the recommendation of the Nomination and Remuneration Committee, approved and granted 16,000 ESOPs under the "Banka BioLoo Limited Employees Stock Option Plan - 2023" ("Plan" or "ESOP 2023" or "Scheme") The details as required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 ('SEBI Circular'), are enclosed in Annexure II.

This intimation shall also be considered as Integrated Filing (Financial) for the quarter and three months ended 30 June 2026 pursuant to the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with relevant SEBI Circulars, as amended and notified from time to time.

We request you to take the aforesaid on record, and to treat the same as compliance with the applicable provisions of the Listing Regulations

The meeting commenced at 02:30 PM and concluded at 5:00 PM.

We request you to kindly take note of the same in your record.

Thank you,

For Banka BioLoo Limited

C Srilakshmi Manjula

Digitally signed by C Srilakshmi Manjula
Date: 2026.08.13 19:23:06 +05'30'

Manjula Chunduru
Company Secretary & Compliance Officer

Encl: As above

Annexure I

Details as required under Regulation 30 of the SEBI Listing Regulations and SEBI Master Circular dated 30th January 2026, as amended from time to time

Particulars	**Mrs. Namita Sanjay Banka**
Reason for change viz. appointment, resignation, removal, death or otherwise	Re-appointment of Mrs. Namita Sanjay Banka, Managing Director, of the Company, who retires by rotation.
Date of appointment & Terms of appointment	Date of Re-appointment: With effect from ensuing Annual General Meeting Terms of Re-appointment: Reappointment of Mrs. Namita Sanjay Banka, Managing Director of the Company, who retires by rotation, subject to the approval of members in the ensuing Annual General Meeting.
Brief Profile	Mrs. Namita Sanjay Banka aged 53 years, is a promoter and Managing Director of the Company. She completed her Bachelor of Science (Home Science) from University of Delhi, and completed Post-Graduate Diploma in Jewellery Designing, Manufacturing & Appraising from Indian Diamond Institute, Surat. She has over 15 years of experience in the sanitation and waste management sector. She has been a guiding force behind the growth and business strategy of our Company.
Disclosure of relationships between directors (in case of appointment of a director)	• Mr. Sanjay Banka (Executive Chairman): Spouse • Mr. Vishal Murarka (Executive Director & Chief Executive Officer): Brother Except as stated above, Mrs. Namita Sanjay Banka is not related to any other Director.
Information as required pursuant to NSE Circular Ref. No. SE/CML/2018/24 dated June 20, 2018	Mrs. Namita Sanjay Banka is not debarred from holding office of Director by virtue of any Securities and Exchange Board of India (SEBI) order or any other such statutory authority.

Annexure II

Details as required under Regulation 30 of the SEBI Listing Regulations and SEBI Master Circular dated 30th January 2026, as amended from time to time

Particulars	Details
Brief details of options granted	16,000 (Sixteen Thousand) Options granted to the eligible employees of the Company under the Banka BioLoo Limited Employees Stock Option Plan – 2023 ("Scheme")
Whether the scheme is in terms of SEBI (SBEBASE) Regulations, 2021 (if applicable)	Yes
Total number of shares covered by these options	16,000 (Sixteen Thousand) Options granted shall be exercisable into 16,000 (Sixteen Thousand) Equity Shares of face value Rs.10/- (Rupee Ten) each.
Pricing Formula	At face value i.e. Rs.10/- (Rupee Ten) each
Options vested	Not Applicable
Vesting schedule	The options would vest in the following manner: i. Upon completion of 12 calendar months from the date of grant; 25% of the Options shall vest; ii. Upon completion of 24 calendar months from the date of grant; 25% of the Options shall vest; iii. Upon completion of 36 calendar months from the date of grant; 25% of the Options shall vest; iv. Upon completion of 48 calendar months from the date of grant; 25% of the Options shall vest;
Time within which option may be exercised	The Options granted can be exercised by the eligible employee within 2 years from the date of vesting of options.
Options exercised	Not Applicable
Money realized by exercise of options	Not Applicable
The total number of shares arising as a result of exercise of option	Not Applicable
Options lapsed	Not Applicable

Variation of terms of options	Not Applicable
Brief details of significant terms	• The terms of the grant of options, provides for the manner in which options would be dealt with, in case of death, permanent incapacity, resignation, termination, retirement, abandonment, etc. • The equity shares allotted, pursuant to the exercise of the stock options, would not be subject to lock-in. • ESOP Shares arising on the conversion of the Options shall rank pari passu with all the other equity Shares of the Company for the time being in issue, from the date of allotment.
Subsequent changes or cancellation or exercise of such options	Not Applicable
Diluted earnings per share pursuant to issue of equity shares on exercise of options.	Not Applicable

STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE QUALIFIED INSTITUTIONS PLACEMENT ETC.

- Not Applicable for this quarter

C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES.

- Not Applicable for this quarter

D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

- Not Applicable for this quarter

E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter)

- Not Applicable for this quarter

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To The Board of Directors of BANKA BIOLOO LIMITED

We have reviewed the accompanying Statement of unaudited standalone financial results of **BANKA BIOLOO LIMITED** for the quarter ended June 30, 2026 (the "statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('the Regulation') as amended, read with SEBI Circular No.CIR/CFD/CMD1/44/2019 dated March 29, 2019 ('the Circular').

1. This Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

2. We conducted our review of the statement in accordance with the Standards on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free from material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

3. Emphasis of Matter

   We draw attention to Note No. 5 to the standalone financial results regarding Trade Receivables (including unbilled revenue) amounting to Rs. 738.61 lakhs are amounts receivable from Government bodies, namely Commissioner & Director of Municipal Administration and Swachha Andhra Corporation. The Company is executing the projects to comply with the project execution terms and to demonstrate that the Company was not at fault in execution of the projects. Management, based on contractual terms of the agreement and Internal assessments and discussions with Authority, is confident of recovering it's present and future dues relating to this project which is supported by favorable interim order from Hon'ble High Court of Telangana. The Company has not made any provision against these receivables.

   Our opinion is not modified in respect of the above matter

B.D. SABOO & ASSOCIATES
Hyderabad
FRN: 003505S
Chartered Accountants

H.O. :Plot No. 235A, Unit No. 401 & 402, 4th Floor, 36 Pinnacle, Road No. 36, Jubilee Hills, Hyderabad - 33.
B.O. : 4-1-358/8, 2nd Floor, Askar Arcade, Hanuman Tekdi, Abids, Hyderabad - 1. Phone : 66783220, 4004778
Email : modani005@gmail.com Website : www.bdsabooassociates.com

4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the aforesaid Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations including the manner in which it is to be disclosed, or that it contain any material misstatement.

For B.D. Saboo and Associates
Chartered Accountants
Firm Registration No: 003505S

B.D. SABOO & ASSOCIATES
Hyderabad
FRN: 003505S
Chartered Accountants

Shyam Sunder Modani
Partner
Membership No: 213530

Place: Hyderabad
Date: 13-08-2026
UDIN: **26213530QDDCNH6892**

Banka BioLoo Limited
Unaudited STANDALONE statement of financial results for the quarter 30.06.2026

Sl. No	Particulars	Quarter Ended			Year Ended
		Unaudited	Audited	Unaudited	Audited
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
1	**Income**				
	Revenue from Operations	1635.78	1802.28	1255.82	5975.76
	Other income	4.18	10.51	105.34	125.42
	Total Income	**1639.96**	**1812.79**	**1361.16**	**6101.18**
2	**Expenses**				
	Cost of materials consumed	656.46	566.77	303.62	1860.38
	Changes in inventories of finished goods and work- in-progress	(23.02)	24.72	(8.25)	24.96
	Operating Expenses	194.15	211.30	162.84	658.79
	Employee benefits expense	592.85	616.52	737.45	2,781.41
	Finance costs	60.76	61.71	59.61	251.64
	Depreciation and amortisation expense	48.08	40.34	41.52	178.41
	Other expenses	68.62	109.83	62.25	338.26
	Total expenses	**1,597.89**	**1,631.21**	**1,359.04**	**6,093.85**
3	**Profit before exceptional items and tax**	**42.07**	**181.59**	**2.12**	**7.33**
4	**Exceptional items**	-	29.52	-	29.52
5	**Profit/(loss) before tax.**	**42.07**	**152.07**	**2.12**	**(22.19)**
6	**Tax expense**				
	(1) Current tax	-	-	-	-
	(2) Taxes for earlier years	-	-	-	-
	(3) MAT Credit	-	-	-	-
	(4) Deferred tax	4.94	(4.99)	(11.43)	(60.40)
	Total Tax expense	**4.94**	**(4.99)**	**(11.43)**	**(60.40)**
7	**Profit after tax**	**37.13**	**157.06**	**13.54**	**38.21**
	Other comprehensive income				
	Items that will not be reclassified to profit and loss				
	Remeasurement of post-employment benefit obligations	-	22.05	-	22.05
	Income tax effect on items that will not be reclassified	-	(5.55)	-	(5.55)
8	**Other comprehensive income for the year**	**-**	**16.50**	**-**	**16.50**
9	**Total comprehensive income for the year**	**37.13**	**173.56**	**13.54**	**54.71**
10	Paid up equity share capital (Face value Rs. 10/- each)	1093.19	1092.24	1088.41	1092.24
11	Earnings per share				
	Basic Earnings per share (in Rs.)	0.34	1.44	0.12	0.35
	Diluted Earnings per share (in Rs.)	0.33	1.44	0.12	0.35
		(Not annualised)	*(Not annualised)*	*(Not annualised)*	*(Annualised)*

For & on behalf of board of directors

Vishal Murarka

Vishal Murarka
CEO & Executive Director
DIN: 06729485

BANKA BIOLOO LIMITED HYDERABAD

Place: Hyderabad
Date: 13.08.2026

Notes:

1. The above unaudited Standalone Financial Results were reviewed by the Audit Committee and then approved by the Board of Directors at their respective meetings held on 13 August 2026.

2. The Standalone Financial Results have been prepared in accordance with Indian Accounting Standards ("IND AS") prescribed under section 133 of the Companies Act 2013 ("the Act") read with the relevant rules issued there under and other accounting principles generally accepted in India and the guidelines issued by SEBI.

3. The above Standalone Financial Results have been prepared in Compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations 2015.

4. With respect to contract and fixed-term employees, the Company has assessed the impact of the new Labour Codes, specifically the Code on Social Security, 2020 (effective 21 November 2025), on its statutory liabilities. Pursuant to Section 53 of the said Code, fixed-term employees are now eligible for gratuity upon completion of one year of service. Based on such assessment, the Company is of the view that the resultant gratuity obligation in respect of such employees is not material to the financial statements and accordingly no provision has been recognised for the quarter ended June 30, 2026.

5. Included in Trade Receivables (including unbilled revenue) amounting to Rs. 738.61 lakhs are amounts receivable from Government bodies, namely Commissioner & Director of Municipal Administration and Swachha Andhra Corporation. The Company is executing the projects to comply with the project execution terms and to demonstrate that the Company was not at fault in execution of the projects. Management, based on contractual terms of the agreement and Internal assessments and discussions with Authority, is confident of recovering it's present and future dues relating to this project which is supported by favorable interim order from Hon'ble High Court of Telangana. The Company has not made any provision against these receivables.

6. The Standalone Financial Results for the quarter ended 30 June 2026 have been prepared following the same accounting policies as those followed for the annual financial statements for the year ended 31 March 2026.

7. Based on the internal reporting provided to the Chief Operating Decision Maker, the standalone financial results relate to the business of waste water & fecal treatment manufacture, supply and installation of and related AMOC services as the only reportable primary segment of the Company as per the Ind AS 108 "Operating Segments".

8. The Company has considered internal and external information up to the date of approval of these standalone financial results in assessing the recoverability of assets including trade receivables, unbilled receivables, based on which it expects to recover the carrying amount of these assets.

9. Figures of previous year / period have been regrouped / recast wherever necessary, to make them comparable.

For **Banka BioLoo Limited**

Vishal Murarka

Vishal Murarka
CEO & Executive Director
DIN: 06729485

BANKA BIOLOO LIMITED HYDERABAD

Place: Hyderabad

Date: 13 August 2026

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
Board of Directors of **BANKA BIOLOO LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **BANKA BIOLOO LIMITED** (The Parent") and its subsidiary (The parent and its subsidiaries and its associate together referred to as the "Group") for the quarter ended 30 June 2026 ("the statement"), being submitted by the Parent Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('the Regulation') as amended, read with SEBI Circular No.CIR/CFD/CMD1/44/2019 dated March 29, 2019 ('the Circular').

2. This Statement, which is the responsibility of the parent's management and approved by the parent Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the statement in accordance with the Standards on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free from material misstatement. A review is Limited primarily to inquiries of the Company personnel and analytical procedures applied to financial data and thus provides less assurance that an audit. We have not performed an audit and, accordingly we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('the Regulation') as amended to the extent applicable.

4. The Statement includes the results of the following entities.

   Holding/Parent Company
   BANKA BIOLOO LIMITED

   Wholly Owned Subsidiary
   ENZOTECH SOLUTIONS PRIVATE LIMITED

   Subsidiary
   MEGALITER VARUNAA PRIVATE LIMITED

   Associate
   SAI BANKA SPV PRIVATE LIMITED (with a share of 50% to the holding company)

B.D. SABOO & ASSOCIATES Hyderabad FRN: 008505S Chartered Accountants

B.D. SABOO & ASSOCIATES
CHARTERED ACCOUNTANTS

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the aforesaid Accounting Standards prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatements.

Emphasis of Matter

We draw attention to Note No. 6 to the consolidated financial results regarding Trade Receivables (including unbilled revenue) amounting to Rs. 738.61 lakhs are amounts receivable from Government bodies, namely Commissioner & Director of Municipal Administration and Swachha Andhra Corporation. The group is executing the projects to comply with the project execution terms and to demonstrate that the group was not at fault in execution of the projects. Management, based on contractual terms of the agreement and Internal assessments and discussions with Authority, is confident of recovering it's present and future dues relating to this project which is supported by favourable interim order from Hon'ble High Court of Telangana. The group has not made any provision against these receivables.

Our opinion is not modified in respect of the above matter

Other Matter

We did not review the interim financial information of 1 subsidiary included in the unaudited consolidated financial results, whose interim financial information reflect total revenues of Rs. 0 Lacs, total net loss of Rs.1.39 Lacs and total comprehensive loss of Rs. 1.39 Lacs for the quarter ended June 30, 2026, as considered in the statement. This interim financial information has not been reviewed by other auditors.

We have reviewed the interim financial information of 1 subsidiary included in the unaudited consolidated financial results, whose interim financial information reflect total revenues of Rs. 164.58 Lacs, total net loss of Rs.9.52 Lacs and total comprehensive loss of Rs. 9.52 Lacs for the quarter ended June 30, 2026, as considered in the statement.

The statement also includes financial results of 1 associate as mentioned above, whose share of net profit after tax of Rs. 0.47 Lacs and total comprehensive income of Rs. 0.47 Lacs for the quarter ended June 30, 2026, as considered in the unaudited consolidated financial results, based on their interim financial results which have not been reviewed and which has been furnished to us by the Management. According to the information and explanations given to us by the management, these unaudited interim standalone financial results are not material to the group.

For B.D. Saboo and Associates
Chartered Accountants
Firm Registration No. 003505s

B.D. SABOO & ASSOCIATES Hyderabad FRN: 003505S Chartered Accountants

Shyam Sundar Modani
Partner
Membership No. 213530
Place: Hyderabad
Date: 13-08-2026
UDIN: **26213530PVQJEK2925**

Banka BioLoo Limited

Unaudited CONSOLIDATED statement of financial results for the quarter ended 30.06.2026

Sl. No	Particulars	Quarter Ended			Year Ended
		Unaudited	Audited	Unaudited	Audited
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
1	**Income**				
	Revenue from Operations	1,055.13	1,767.46	1,114.12	5,709.24
	Other income	10.21	13.83	105.34	129.37
	Total Income	**1,065.34**	**1,781.29**	**1,219.46**	**5,838.61**
2	**Expenses**				
	Cost of materials consumed	40.21	465.35	124.22	1,376.96
	Changes in inventories of finished goods and work- in-progress	(23.02)	24.72	(8.25)	24.96
	Operating Expenses	194.15	211.30	162.84	658.79
	Employee benefits expense	592.85	616.52	737.45	2,781.41
	Finance costs	116.16	92.60	89.42	368.83
	Depreciation and amortisation expense	84.77	68.89	63.84	280.14
	Other expenses	69.29	112.27	63.61	347.41
	Total expenses	**1,074.40**	**1,591.65**	**1,233.14**	**5,838.50**
3	Share of profit/(loss) of Associates	0.47	(2.34)	1.15	2.93
4	**Profit/(loss) before tax exceptional items**	**(8.59)**	**187.29**	**(12.53)**	**3.04**
5	**Exceptional items**	-	29.52	-	29.52
6	**Profit/(loss) before tax**	**(8.59)**	**157.77**	**(12.53)**	**(26.48)**
7	**Tax expense**				
	(1) Current tax	-	-	-	-
	(2) Taxes for earlier years	-	-	-	-
	(3) MAT Credit	-	-	-	-
	(4) Deferred tax	(4.66)	(2.63)	(12.74)	(65.79)
	Total Tax expense	**(4.66)**	**(2.63)**	**(12.74)**	**(65.79)**
8	**Profit after tax**	**(3.93)**	**160.41**	**0.21**	**39.31**
	Other comprehensive income				
	Items that will not be reclassified to profit and loss				
	Remeasurement of post-employment benefit obligations	-	22.05	-	22.05
	Income tax effect on items that will not be reclassified to	-	(5.55)	-	(5.55)
9	**Other comprehensive income for the year**	**-**	**16.50**	**-**	**16.50**
10	**Total comprehensive income for the year**	**(3.93)**	**176.90**	**0.21**	**55.81**
	Attributable to				
	Shareholders of the Company	(1.34)	174.47	0.51	51.63
	Non controlling interest	(2.59)	2.44	(0.30)	4.18
11	Paid up equity share capital (Face value Rs. 10/- each)	1,093.19	1,092.24	1,088.41	1,092.24
12	Earnings per share				
	Basic Earnings per share (in Rs.)	(0.01)	1.45	0.00	0.32
	Diluted Earnings per share (in Rs.)	(0.01)	1.43	0.00	0.32
		(Not annualised)	*(Not annualised)*	*(Not annualised)*	*(Annualised)*

For & on behalf of board of directors

Vishal Murarka
CEO & Executive Director
DIN: 06729485

BANKA BIOLOO LIMITED HYDERABAD

Place: Hyderabad
Date: 13.08.2026

Notes:

1. The above statement of unaudited Consolidated Financial Results of the Banka BioLoo Limited ("Holding Company") and its subsidiaries (together referred as "Group"), associates were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 13 August 2026.

2. The Consolidated Financial Results have been prepared in accordance with Indian Accounting Standards ("INDAS") prescribed under section 133 of the Companies Act 2013 ("the Act") read with the relevant rules issued there under and other accounting principles generally accepted in India and the guidelines issued by SEBI.

3. The consolidated financial results of the Group include the results of the company and results of the following entities.

Name of the entity	Status
Enzotech Solutions Pvt Ltd	Wholly owned subsidiary
Megaliter Varunaa Pvt Ltd	Subsidiary
Sai Banka SPV Pvt Ltd	Associate with 50% share to the Company

4. The above Consolidated Financial Results have been prepared in Compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations 2015.

5. With respect to contract and fixed-term employees, the Group has assessed the impact of the new Labour Codes, specifically the Code on Social Security, 2020 (effective 21 November 2025), on its statutory liabilities. Pursuant to Section 53 of the said Code, fixed-term employees are now eligible for gratuity upon completion of one year of service. Based on such assessment, the Group is of the view that the resultant gratuity obligation in respect of such employees is not material to the financial statements and accordingly no provision has been recognised for the quarter ended June 30, 2026.

6. Included in Trade Receivables (including unbilled revenue) amounting to Rs. 738.61 lakhs are amounts receivable from Government bodies, namely Commissioner & Director of Municipal Administration and Swachha Andhra Corporation. The group is executing the projects to comply with the project execution terms and to demonstrate that the group was not at fault in execution of the projects. Management, based on contractual terms of the agreement and Internal assessments and discussions with Authority, is confident of recovering it's present and future dues relating to this project which is supported by favourable interim order from Hon'ble High Court of Telangana. The group has not made any provision against these receivables.

7. The Consolidated Financial Results for the quarter ended 30 June 2026 have been prepared following the same accounting policies as these followed for the annual financial statements for the year ended 31 March 2026.

8. Based on the internal reporting provided to the Chief Operating Decision Maker, the consolidated financial results relate to the business of waste water & fecal treatment manufacture, supply and installation of and related AMOC services as the only reportable primary segment of the Group as per the Ind AS 108 "Operating Segments".

9. The Group has considered internal and external information up to the date of approval of these Consolidated financial results in assessing the recoverability of assets including trade receivables, unbilled receivables, based on which it expects to recover the carrying amount of these assets.

10. Figures of previous year / period have been regrouped / recast wherever necessary, to make them comparable.

For **Banka BioLoo Limited**

Vishal Murarka

Vishal Murarka
CEO & Executive Director
DIN: 06729485

BANKA BIOLOO LIMITED
HYDERABAD

Place: Hyderabad
Date: 13 August 2026